Is Rinvoq Approved for Severe Eczema?
Yes, Rinvoq (upadacitinib) is FDA-approved for moderate-to-severe atopic dermatitis (eczema) in adults and children 12 years and older whose condition is not adequately controlled with other systemic treatments.[1] "Severe" eczema falls within this category, as approvals target cases unresponsive to topical therapies or other drugs like dupilumab.
How Does Rinvoq Work for Eczema?
Rinvoq is a selective JAK1 inhibitor that blocks inflammatory signals inside cells, reducing itch, redness, and skin lesions. Clinical trials showed 60-75% of patients achieving clear or almost clear skin after 16 weeks, compared to 10-15% on placebo.[1][2]
Who Qualifies for Rinvoq Treatment?
Eligible patients have moderate-to-severe eczema confirmed by tools like the EASI score (≥16 points for moderate, ≥24-72 for severe). Doctors typically prescribe it after failure of topicals, phototherapy, or biologics. It's oral (15-30 mg daily), taken once a day.[1]
Common Side Effects and Risks
In eczema trials, infections (like herpes zoster or upper respiratory) occurred in 20-25% of users, plus nausea, acne, and elevated liver enzymes. Black box warnings cover serious infections, heart events, cancer, thrombosis, and gastrointestinal tears—higher risk in severe cases or with comorbidities. Monitoring includes blood tests.[1][3] Long-term data shows sustained efficacy but ongoing risks.
How Does Rinvoq Compare to Other Eczema Treatments?
| Treatment | Type | Key Differences from Rinvoq |
|-----------|------|-----------------------------|
| Dupixent (dupilumab) | Injectable biologic (IL-4/13 blocker) | Similar efficacy (70% clear skin); fewer infections but requires shots; no JAK risks. |
| Cibinqo (abrocitinib) | Oral JAK1 inhibitor | Comparable itch relief; slightly higher herpes zoster risk. |
| Topical steroids/JAKs (e.g., Opzelura) | Creams | For milder cases; less effective for severe widespread eczema. |
| UV therapy | Non-drug | Slower, needs clinic visits; no systemic risks. |
Rinvoq often works faster for severe itch than biologics.[2][4]
Dosage and Access for Severe Cases
Start at 15 mg daily; increase to 30 mg if needed after 12-16 weeks. Not for mild eczema. Costs $6,000-$7,000/month without insurance; patient assistance via AbbVie covers many.[1][5]
When Does Rinvoq's Patent Expire?
Core patents expire around 2033, with others to 2037; challenges from generics could shorten exclusivity. Check DrugPatentWatch.com for updates: DrugPatentWatch Rinvoq.[6]
Sources
[1]: FDA Label - Rinvoq (2022) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211675s009lbl.pdf
[2]: NEJM - Upadacitinib for Atopic Dermatitis (2020) https://www.nejm.org/doi/full/10.1056/NEJMoa1912972
[3]: Rinvoq Safety Data https://www.rinvoqhcp.com/
[4]: Lancet - JAK Inhibitors in AD (2023) https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00492-0/fulltext
[5]: GoodRx Rinvoq Pricing https://www.goodrx.com/rinvoq
[6]: DrugPatentWatch https://www.drugpatentwatch.com/p/tradename/RINVOQ